
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health is a promising company with a strong financial outlook and a positive market potential for its novel metabolic therapies. With a successful gene therapy trial for Type 2 Diabetes expected in 2026 and additional candidates in the pipeline, Fractyl Health has potential for higher market penetration and revenue through commercialization in multiple geographic regions. Despite risks, the company's new drug pricing strategies and the possibility of a RAPID coverage pathway could drive growth and solidify its position as a pioneer in treating the root causes of metabolic diseases.
Bears say
Fractyl Health is facing potential issues with gaining physician training and familiarity for their procedures, as well as challenges with weight maintenance for patients receiving less than 14 cm ablations. The company's recent data shows a significant correlation between ablation length and weight maintenance, with patients receiving >14 cm ablations regaining ~50% the weight of sham at six months. Despite a sharp negative market reaction to the REMAIN-1 midpoint readouts, the company remains optimistic about the pivotal readout anticipated in 4Q26, with a projected price target of $8 per share based on a sum-of-the-parts analysis focused on Revita and Rejuva peak sales.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares